Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Can medicine mend a broken heart?

Posted on November 18th, 2015 by

Chemistry

broken-heart-cookie_lr

I freely admit, life without chocolate is unthinkable. That my daily sugar rush may lead to diabetes or blocked arteries (among other things) is something I prefer not to think about. Continue reading “Can medicine mend a broken heart?” »

Screening Scientific Literature for Adverse Drug Reactions: Relevant for Patient Safety or Just a Time-Consuming Regulatory Obligation?

Posted on November 16th, 2015 by

Pharmacovigilance

mag_glass_resized

An adverse drug reaction (ADR) is defined as any response to a medicinal product which is noxious and unintended. ADRs are a major public health problem, accounting for up to 5% of all hospital admissions and 28% of the emergency visits. Of all hospitalized patients, 5% experience an ADR during the hospitalization Continue reading “Screening Scientific Literature for Adverse Drug Reactions: Relevant for Patient Safety or Just a Time-Consuming Regulatory Obligation?” »

Eluding a Post-Antibiotic Era: The Challenge of Designing Novel Antibiotics

Posted on November 13th, 2015 by

Pharma R&D

MRSA bacteria. Computer artwork of methicillin-resistant Staphylococcus aureus (MRSA) bacteria.

As cases of drug-resistant pathogens multiply, the WHO warns of a “post-antibiotic era.” Designing novel antibiotics, however, remains a scientific challenge because achieving therapeutic efficacy requires painstaking testing of compound properties that often conflict. Continue reading “Eluding a Post-Antibiotic Era: The Challenge of Designing Novel Antibiotics” »

The Importance of Literature on Medical Device Development and Post Market Surveillance

Posted on November 13th, 2015 by

Chemistry

Medical devices

Before the ideation and creation of a novel prototype device — or the establishment of a new purpose for an existing one — medical device manufacturers must be confident that the device will serve a real need in the market. They must also establish that the device has unique value and will be safe and effective. Continue reading “The Importance of Literature on Medical Device Development and Post Market Surveillance” »

Using Reaxys for Lead Optimization: A Case Study

Posted on November 13th, 2015 by

Pharma R&D

dr-tucci

Epigen Biosciences is a start-up pharmaceutical company that collaborates with academic groups to discover innovative drugs for a range of medical conditions, including renal diseases, cancer and CNS disorders. Co-founder Dr. Fabio Tucci met with Elsevier to discuss how Epigen researchers use Reaxys to support their application of advanced hit-to-lead and lead optimization methods. Continue reading “Using Reaxys for Lead Optimization: A Case Study” »

Best Practices for Post-Market Surveillance Processes

Posted on November 13th, 2015 by

Pharmacovigilance

Medical-safety-2

Donna Sees, an Information Consultant with PharmIntell Consulting, has been a librarian in the medical field for more than 10 years. In this article, she discusses post-market surveillance processes and best practices for medical device companies.

Learn how PharmIntell Consulting took advantage of QUOSA.

  1. 1
  2. 52
  3. 53
  4. 54
  5. 55
  6. 56


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.